Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical study

Global Dermatology Access Study by L'Oréal, ILDS

Analysis based on 11 articles · First reported Sep 16, 2026 · Last updated Sep 16, 2026

Sentiment
5
Attention
1
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study is a reputational and public-health milestone for L Oréal's dermocosmetics franchise and could support long-term demand for dermatological products and services, though it carries no near-term earnings effect. Broader market impact is minimal, with modest positive read-through for dermocosmetics, telemedicine and AI-diagnostics themes.

dermocosmetics healthcare pharmaceuticals

L Oréal Dermatological Beauty and the The International League of Dermatological Societies published the Global Access to Skin Health Observatory Study in JAMA Dermatology on September 16, 2026. The first comprehensive global assessment of dermatological care spans 158 countries and 97% of the world population. It finds a global mean of 2.66 dermatologists per 100,000 people against an estimated benchmark of 5.63, leaving over 80% of countries below adequate levels. Density ranges from 0.37 per 100,000 in low-income countries to 5.05 in high-income countries, with no African or South-East Asian country reaching the benchmark. 79% of dermatologists are urban-based, rising to 91% in low-income countries, creating dermatological deserts. 74% of countries report skin health is not a national government priority, and 42% report poor or inadequate access to dermatological care. The study supports implementation of the World Health Assembly 2025 Resolution on Skin Diseases as a Global Public Health Priority. Principal investigator Esther E. Freeman of Harvard Medical School and the International Foundation for Dermatology said the data turns anecdote into actionable evidence. Myriam Cohen-Welgryn, President of L Oréal Dermatological Beauty, said access to skin health should be a right, not a privilege. The work falls under L Oréal's 20-million-euro, five-year Act for Dermatology programme launched in March 2025. Data is housed in the Skin Observatory Data Explorer for health ministries, researchers and stakeholders.

50 L Oréal launched Act for Dermatology
stock
Co-publisher and funder of the study through its Dermatological Beauty division and Act for Dermatology programme, reinforcing its leadership in dermocosmetics and global skin-health access.
Importance 95.0 Sentiment 15.0
ngo
Co-author of the landmark global study, elevating the organization's role as the leading global dermatology body setting evidence-based care benchmarks.
Importance 90.0 Sentiment 10.0
per
Principal investigator of the study and vice chair of the International Foundation for Dermatology, serving as its lead scientific voice.
Importance 65.0 Sentiment 5.0
per
President of L Oréal Dermatological Beauty, she is the corporate face of the study and of L Oréal's skin-health access commitments.
Importance 60.0 Sentiment 10.0
ngo
Its vice chair Esther E. Freeman led the study, tying the foundation to the global dermatology access agenda.
Importance 35.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.